Mycosis fungoides (MF) is a chronic disease, causing serious morbidities and mortality. This study was designed to measure depression and anxiety levels in MF patients, and quality of life (QoL) assessments and to compare the results with controls. Fifty-two patients with a diagnosis of MF and 52 age and sex matching healthy controls were enrolled in this study. Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI) and the 36-Item Short Form Health Survey (SF-36) were administered to all patients and controls. Mean BAI and BDI scores of the patients with MF were significantly higher than controls. In case of the SF-36, general health perception, emotional, and social functioning scores were significantly lower in MF patients. Depression scores of the patients' were positively correlated with the age of disease onset and negatively correlated with physical functioning scores. Significant negative correlation was detected between eight subscales of the SF-36 and BDI and BAI scores. This study has demonstrated that there is significant impairment of QoL in MF patients MF, with higher anxiety and depression levels, when compared to control group. As the disease progresses, level of depression increases and patients' general health perception deteriorates.
Background/aim: Autoimmune bullous diseases, if left untreated, are life-threatening conditions affecting primarily skin and mucous membranes. These blistering disorders are characterized by epidermal or subepidermal detachment. Autoimmunity has the key role in pathogenesis, therefore immunosuppressive agents are the treatment of choice. The aim of this study is to document relative frequencies of different autoimmune bullous diseases, patient characteristics, treatment options and side effects in patients presenting to our bullous skin disease center, at
Click https://www.wileyhealthlearning.com/ced.aspx for the corresponding questions to this CME article.
Acne vulgaris is a multifactorial disorder of the pilosebaceous unit. The clinical picture can range from mild comedones to fulminant, scarring cases. Approximately 83-100% of all adolescents experience acne vulgaris at some point of their lives. Although acne often tends to resolve following the adolescent period, many men and women continue to suffer from either active acne or postinflammatory scars into their twenties and thirties. Most patients with acne vulgaris are in the complicated adolescence period and thus carry a distinctive psychosocial burden. They possess a disease stigma on their skin for the external world to criticize every day. For all these reasons, acne is a disease which should be treated promptly and efficiently in all age groups. This chapter will provide a comprehensive and up-to-date review of pathophysiology of acne vulgaris, new molecular mechanisms on the evolving acne lesions, epidemiology of the disease, and latest treatment options. The molecular biology of acne lesions, novel treatment options including cosmetic approaches, their role in acne pathogenesis, pathophysiology, and mechanism of actions of the drugs, safety, and efficacy issues, and various treatment regimens will be discussed along with novel discoveries and areas in which further research is needed.
Introduction: Chronic paronychia (CP) is an inflammatory disease of the nail folds. Staging of CP is important for clinicians. We developed an objective scale that evaluates each finding of CP separately in addition to evaluating the treatment process and follow-up. Methods: A new “chronic paronychia severity index scale” was developed to enable dermatologists to examine all features of CP. A previous categorical severity scale and this new scale were used for the evaluation of CP by 6 different dermatologists. The dermatologists evaluated the nails with both scales again 20 days later using randomly ordered photographs. Results: Using the previous scale, the intra-observer intraclass correlation coefficient (ICC) values between the first and second evaluations were 0.767, 0.860, 0.734, 0.609, 0.900, and 0.840 for the 6 dermatologists. Using the new proposed scale, the intra-observer ICC values between the first and second evaluations were 0.930, 0.931, 0.942, 0.934, 0.938, and 0.920 for the 6 dermatologists. All intra-observer ICC values were higher for the results of the proposed scale than for those of the previous scale. The inter-observer ICC values were also higher for the proposed scale than for the previous scale for the 6 dermatologists. Conclusion: The new scale is a standardized, more suitable, objective, and valuable method to use in clinical practice and studies on CP.
This study aims to determine the efficacy of omalizumab, a humanized monoclonal anti‐immunoglobulin E antibody, in patients with chronic spontaneous urticaria (CSU) refractory to conventional therapy, together with the evaluation of serum CRP levels. All the patients with a diagnosis of CSU who were continuously treated with omalizumab (300 mg/mo) for at least 3 months between June 2016 and July 2019 were included in this study. Urticaria activity score (UAS‐7) was used for assessment of disease activity. Serum CRP levels were also retrospectively analyzed. When UAS‐7 scores before the initiation of therapy were compared to the week 4, 12, 24, and 36 scores after the treatment, each were significantly different from the pretreatment results (P < .01). CRP level prior to treatment was found to be strongly correlated with baseline UAS scores of the patients' (P = .00). At the 12th week of treatment, decline of CRP level was positively and strongly correlated with the decline of UAS (P = .037). In this study, mean UAS decreased, mean rescue medication use declined, and overall therapeutic response improved with omalizumab treatment. Additionally, significant correlation between the decline of CRP levels and treatment response was found.
Summary Background Cutaneous ulcers of Behçet disease (BD) are rare but have high morbidity and resistance to conventional therapies. An important and essential aspect of ulcer management is debridement. Regarding maggot therapy (MT), excretions of the green bottle fly, Lucilia sericata, have been shown to have the ability to remove necrotic debris and promote healing. Aim To evaluate the efficacy of MT for cutaneous ulcers of BD. Methods In this open‐label trial, patients with BD with refractory leg ulcers suitable for MT were enrolled. Maggot application was performed until complete debridement was achieved, and all patients were followed up for 12 months afterwards to assess the total healing of ulcers. Results In total, 24 patients with 32 ulcers were enrolled. Using MT, 91.6% of all ulcers were completely debrided. Mean time to debridement was 14.9 days and mean number of cycles required was 5.3. Mean ulcer size was decreased by 23% with treatment. Time to debridement was positively correlated with pretreatment ulcer size and ulcer duration (P = 0.01 and P < 0.01) but not with ulcer depth, comorbidities, smoking, age or sex (P > 0.05 for all). During follow‐up, 79.1% of all ulcers healed completely. Mean time required for total healing was positively correlated with ulcer duration, pretreatment and post‐treatment ulcer area, ulcer depth and mean time to total debridement (P < 0.03, P = 0.00, P = 0.04 and P < 0.01, respectively). Conclusions To our knowledge, the findings presented in this first and unique study may provide key answers about factors affecting success rate of MT in BD cutaneous ulcers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.